Facioscapulohumeral muscular dystrophy

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 4, 2015, Pages 607-614

  Sacconi, Sabrina ^a,b   Salviati, Leonardo ^c,d   Desnuelle, Claude ^a,b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b CENTRE DE BIOCHIMIE   (France)

^c UNIVERSITY OF PADOVA   (Italy)

^d Pediatric Research Institute   (Italy)

Author keywords

DNA methylation; DUX4; Epigenetics; Facioscapulohumeral muscular dystrophy; SMCHD1; Subtelomeric repeat

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CORTICOSTEROID; FOLIC ACID; METHIONINE; MYOSTATIN; SMALL INTERFERING RNA; CHROMATIN; DUX4 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; NONHISTONE PROTEIN; SMCHD1 PROTEIN, HUMAN;

CELL TRANSPLANTATION; CHROMATIN CONDENSATION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE COURSE; DNA METHYLATION; DUX4 GENE; EPIGENETICS; EXERCISE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 2; GENE; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE THERAPY; HUMAN; NEUROMUSCULAR ELECTRICAL STIMULATION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOTHERAPY; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN STABILITY; REVIEW; ALLELE; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 4; GENETIC DISEASES, INBORN; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUSCULAR DYSTROPHIES; MUTATION; NUCLEOTIDE REPEAT; PATHOLOGY;

ALLELES; ANIMALS; APOPTOSIS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOMES, HUMAN, PAIR 4; EPIGENESIS, GENETIC; GENETIC DISEASES, INBORN; GENETIC LOCI; HOMEODOMAIN PROTEINS; HUMANS; MUSCULAR DYSTROPHIES; MUTATION; REPETITIVE SEQUENCES, NUCLEIC ACID;

EID: 84922275798     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.05.021     Document Type: Review

References (82)

1. Arahata K., Ishihara T., Fukunaga H., Orimo S., Lee J.H., Goto K., et al. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve Suppl. 1995, 2:S56-S66.
2. Frisullo G., Frusciante R., Nociti V., Tasca G., Renna R., Iorio R., et al. CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J. Clin. Immunol. Apr 2011, 31(2):155-166.
3. Rogers M. Facioscapulohumeral muscular dystrophy: historical background and literature review. Facioscapulohumeral Muscular Dystrophy Clinical Medicine and Molecular Cell Biology 2004, Garland Science/BIOS Scientific Publishers, Oxon, United Kingdom. M. Upadhyaya, D.N. Cooper (Eds.).
4. Tawil R., McDermott M.P., Mendell J.R., Kissel J., Griggs R.C. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group. Neurology Mar 1994, 44(3 Pt 1):442-446.
5. Funakoshi M., Goto K., Arahata K. Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy. Neurology Jun 1998, 50(6):1791-1794.
6. Miura K., Kumagai T., Matsumoto A., Iriyama E., Watanabe K., Goto K., et al. Two cases of chromosome 4q35-linked early onset facioscapulohumeral muscular dystrophy with mental retardation and epilepsy. Neuropediatrics Oct 1998, 29(5):239-241.
7. Chen T.H., Lai Y.H., Lee P.L., Hsu J.H., Goto K., Hayashi Y.K., et al. Infantile facioscapulohumeral muscular dystrophy revisited: expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul. Disord. Apr 2013, 23(4):298-305.
8. Statland J.M., Sacconi S., Farmakidis C., Donlin-Smith C.M., Chung M., Tawil R. Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. Neurology Mar 26 2013, 80(13):1247-1250.
9. Padberg G. Facioscapulohumeral muscular dystrophy: a clinician's experience. Facioscapulohumeral Muscular Dystrophy Clinical Medicine and Molecular Cell Biology 2004, Garland Science/BIOS Scientific Publishers, Oxon, United Kingdom. M. Upadhyaya, D.N. Cooper (Eds.).
10. Bonifazi E., Lamperti C., Fiorillo C., Vercelli L., Borsato C., Frusciante R., et al. Unexpected high percentage of asymptomatic subjects carrying the FSHD molecular defect: which factors contribute to the disease mechanism?. Neuromuscul. Disord. Sep 2009, 19(8-9):649-650.
11. Scionti I., Greco F., Ricci G., Govi M., Arashiro P., Vercelli L., et al. Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. Apr 6 2012, 90(4):628-635.
12. Sacconi S., Lemmers R.J., Balog J., van der Vliet P.J., Lahaut P., van Nieuwenhuizen M.P., et al. The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am. J. Hum. Genet. Oct 3 2013, 93(4):744-751.
13. Zatz M., Marie S.K., Cerqueira A., Vainzof M., Pavanello R.C.M., Passos-Bueno M.R. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females. Am. J. Med. Genet. May 1 1998, 77(2):155-161.
14. Tawil R., Van Der Maarel S.M. Facioscapulohumeral muscular dystrophy. Muscle Nerve Jul 2006, 34(1):1-15.
15. Wohlgemuth M., van der Kooi E.L., van Kesteren R.G., van der Maarel S.M., Padberg G.W. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology Jul 13 2004, 63(1):176-178.
16. Scully M.A., Eichinger K.J., Donlin-Smith C.M., Tawil R., Statland J.M. Restrictive lung involvement in facioscapulohumeral muscular dystrophy. Muscle Nerve Feb 23 2014, http://dx.doi.org.10.1002/mus.24218.
17. Della Marca G., Frusciante R., Vollono C., Iannaccone E., Dittoni S., Losurdo A., et al. Pain and the alpha-sleep anomaly: a mechanism of sleep disruption in facioscapulohumeral muscular dystrophy. Pain Med. Apr 2013, 14(4):487-497.
18. Tawil R. Facioscapulohumeral muscular dystrophy. Neurotherapeutics Oct 2008, 5(4):601-606.
19. Fitzsimons R.B. Facioscapulohumeral muscular dystrophy. Curr. Opin. Neurol. Oct 1999, 12(5):501-511.
20. Balatsouras D.G., Korres S., Manta P., Panousopoulou A., Vassilopoulos D. Cochlear function in facioscapulohumeral muscular dystrophy. Otol. Neurotol. Jan 2007, 28(1):7-10.
21. Trevisan C.P., Pastorello E., Ermani M., Angelini C., Tomelleri G., Tonin P., et al. Facioscapulohumeral muscular dystrophy: a multicenter study on hearing function. Audiol. Neurootol. 2008, 13(1):1-6.
22. Trevisan C.P., Pastorello E., Armani M., Angelini C., Nante G., Tomelleri G., et al. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. Eur. Neurol. 2006, 56(1):1-5.
23. Wohlgemuth M., de Swart B.J.M., Kalf J.G., Joosten F.B.M., Van der Vliet A.M., Padberg G.W. Dysphagia in facioscapulohumeral muscular dystrophy. Neurology Jun 27 2006, 66(12):1926-1928.
24. Di Lazzaro V., Oliviero A., Tonali P.A., Felicetti L., De Marco M.B., Saturno E., et al. Changes in motor cortex excitability in facioscapulohumeral muscular dystrophy. Neuromuscul. Disord. Jan 2004, 14(1):39-45.
25. Quarantelli M., Lanzillo R., Del Vecchio W., Mollica C., Prinster A., Iadicicco L., et al. Modifications of brain tissue volumes in facioscapulohumeral dystrophy. NeuroImage Sep 2006, 32(3):1237-1242.
26. de Greef J.C., Lemmers R.J., Camaño P., Day J.W., Sacconi S., Dunand M., et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology Oct 26 2010, 75(17):1548-1554.
27. Gendrel A.V., Tang Y.A., Suzuki M., Godwin J., Nesterova T.B., Greally J.M., et al. Epigenetic functions of smchd1 repress gene clusters on the inactive X chromosome and on autosomes. Mol. Cell. Biol. Aug 2013, 33(16):3150-3165.
28. Zatz M., Marie S.K., Passos-Bueno M.R., Vainzof M., Campiotto S., Cerqueira A., et al. High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am. J. Hum. Genet. Jan 1995, 56(1):99-105.
29. Bakker E., Wijmenga C., Vossen R.H., Padberg G.W., Hewitt J., van der Wielen M., et al. The FSHD-linked locus D4F104S1 (p13E-11) on 4q35 has a homologue on 10qter. Muscle Nerve 1995, 2:S39-S44.
30. Wijmenga C., Padberg G.W., Moerer P., Wiegant J., Liem L., Brouwer O.F., et al. Mapping of facioscapulohumeral muscular dystrophy gene to chromosome 4q35-qter by multipoint linkage analysis and in situ hybridization. Genomics Apr 1991, 9(4):570-575.
31. Mathews K.D., Mills K.A., Bosch E.P., Ionasescu V.V., Wiles K.R., Buetow K.H., et al. Linkage localization of facioscapulohumeral muscular dystrophy (FSHD) in 4q35. Am. J. Hum. Genet. Aug 1992, 51(2):428-431.
32. Upadhyaya M., Lunt P., Sarfarazi M., Broadhead W., Farnham J., Harper P.S. The mapping of chromosome 4q markers in relation to facioscapulohumeral muscular dystrophy (FSHD). Am. J. Hum. Genet. Aug 1992, 51(2):404-410.
33. Deidda G., Cacurri S., Piazzo N., Felicetti L. Direct detection of 4q35 rearrangements implicated in facioscapulohumeral muscular dystrophy (FSHD). J. Med. Genet. May 1996, 33(5):361-365.
34. Tawil R., Forrester J., Griggs R.C., Mendell J., Kissel J., McDermott M., et al. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. Ann. Neurol. Jun 1996, 39(6):744-748.
35. van Deutekom J.C., Lemmers R.J., Grewal P.K., van Geel M., Romberg S., Dauwerse H.G., et al. Identification of the first gene (FRG1) from the FSHD region on human chromosome 4q35. Hum. Mol. Genet. May 1996, 5(5):581-590.
36. van Overveld P.G., Enthoven L., Ricci E., Rossi M., Felicetti L., Jeanpierre M., et al. Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Ann. Neurol. Oct 2005, 58(4):569-576.
37. Cacurri S., Piazzo N., Deidda G., Vigneti E., Galluzzi G., Colantoni L., et al. Sequence homology between 4qter and 10qter loci facilitates the instability of subtelomeric KpnI repeat units implicated in facioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. Jul 1998, 63(1):181-190.
38. Lemmers R.J., van der Maarel S.M., van Deutekom J.C., van der Wielen M.J., Deidda G., Dauwerse H.G., et al. Inter- and intrachromosomal sub-telomeric rearrangements on 4q35: implications for facioscapulohumeral muscular dystrophy (FSHD) aetiology and diagnosis. Hum. Mol. Genet. Aug 1998, 7(8):1207-1214.
39. Lemmers R.J., Wohlgemuth M., van der Gaag K.J., van der Vliet P.J., van Teijlingen C.M., de Knijff P., et al. Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. Nov 2007, 81(5):884-894.
40. Lemmers R.J., van der Vliet P.J., Klooster R., Sacconi S., Camano P., Dauwerse J.G., et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science Sep 24 2010, 329(5999):1650-1653.
41. Lemmers R.J., van der Vliet P.J., van der Gaag K.J., Zuniga S., Frants R.R., de Knijff P., et al. Worldwide population analysis of the 4q and 10q subtelomeres identifies only four discrete interchromosomal sequence transfers in human evolution. Am. J. Hum. Genet. Mar 12 2010, 86(3):364-377.
42. Spurlock G., Jim H.P., Upadhyaya M. Confirmation that the specific SSLP microsatellite allele 4qA161 segregates with fascioscapulohumeral muscular dystrophy (FSHD) in a cohort of multiplex and simplex FSHD families. Muscle Nerve Nov 2010, 42(5):820-821.
43. Tsumagari K., Chang S.C., Lacey M., Baribault C., Chittur S.V., Sowden J., et al. Gene expression during normal and FSHD myogenesis. BMC Med. Genet. Sep 2011, 27:4.
44. Lemmers R.J., Osborn M., Haaf T., Rogers M., Frants R.R., Padberg G.W., et al. D4F104S1 deletion in facioscapulohumeral muscular dystrophy: phenotype, size, and detection. Neurology Jul 22 2003, 61(2):178-183.
45. Deak K.L., Lemmers R.J.L.F., Stajich J.M., Klooster R., Tawil R., Frants R.R., et al. Genotype-phenotype study in an FSHD family with a proximal deletion encompassing p13E-11 and D4Z4. Neurology Feb 20 2007, 68(8):578-582.
46. Lemmers R.J., van der Wielen M.J., Bakker E., Padberg G.W., Frants R.R., van der Maarel S.M. Somatic mosaicism in FSHD often goes undetected. Ann. Neurol. Jun 2004, 55(6):845-850.
47. Nguyen K., Walrafen P., Bernard R., Attarian S., Chaix C., Vovan C., et al. Molecular combing reveals allelic combinations in facioscapulohumeral dystrophy. Ann. Neurol. Oct 2011, 70(4):627-633.
48. Papanikos F., Skoulatou C., Sakellariou P., Kekou K., Christopoulos T.K., Kanavakis E., et al. A simplified approach for FSHD molecular testing. Clin. Chim. Acta Feb 15 2014, 429:96-103.
49. Sacconi S., Salviati L., Bourget I., Figarella D., Péréon Y., Lemmers R., et al. Diagnostic challenges in facioscapulohumeral muscular dystrophy. Neurology Oct 24 2006, 67(8):1464-1466.
50. Sacconi S., Camaño P., de Greef J.C., Lemmers R.J., Salviati L., Boileau P., et al. Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity. J. Med. Genet. Jan 2012, 49(1):41-46.
51. Tupler R., Berardinelli A., Barbierato L., Frants R., Hewitt J.E., Lanzi G., et al. Monosomy of distal 4q does not cause facioscapulohumeral muscular dystrophy. J. Med. Genet. May 1996, 33(5):366-370.
52. Hewitt J.E., Lyle R., Clark L.N., Valleley E.M., Wright T.J., Wijmenga C., et al. Analysis of the tandem repeat locus D4z4 associated with facioscapulohumeral muscular-dystrophy. Hum. Mol. Genet. Aug 1994, 3(8):1287-1295.
53. Winokur S.T., Bengtsson U., Wasmuth J.J., Altherr M.R. Mildly repetitive sequences closely linked to the facioscapulohumeral muscular-dystrophy gene on distal chromosome 4q cross-hybridize to regions of heterochromatin. Cytogenet. Cell Genet. 1994, 66(4):S32-S38.
54. Lee J.H., Goto K., Matsuda C., Arahata K. Characterization of a tandemly repeated 3.3-kb Kpni unit in the facioscapulohumeral muscular-dystrophy (FSHD) gene region on chromosome 4q35. Muscle Nerve 1995, S6-S13.
55. Gabriels J., Beckers M.C., Ding H., De Vriese A., Plaisance S., van der Maarel S.M., et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3kb element. Gene Aug 5 1999, 236(1):25-32.
56. Dixit M., Ansseau E., Tassin A., Winokur S., Shi R., Qian H., et al. DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc. Natl. Acad. Sci. U. S. A. Nov 13 2007, 104(46):18157-18162.
57. Clapp J., Mitchell L.M., Bolland D.J., Fantes J., Corcoran A.E., Scoffing P.J., et al. Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. Aug 2007, 81(2):264-279.
58. Geng L.N., Yao Z., Snider L., Fong A.P., Cech J.N., Young J.M., et al. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev. Cell Jan 17 2012, 22(1):38-51.
59. Young J.M., Whiddon J.L., Yao Z., Kasinathan B., Snider L., Geng L.N., et al. DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis. PLoS Genet. Nov 2013, 9(11):e1003947.
60. Wallace L.M., Garwick S.E., Mei W., Belayew A., Coppee F., Ladner K.J., et al. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann. Neurol. Mar 2011, 69(3):540-552.
61. Krom Y.D., Thijssen P.E., Young J.M., den Hamer B., Balog J., Yao Z., et al. Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD. PLoS Genet. Apr 2013, 9(4):e1003415.
62. Lemmers R.J., Tawil R., Petek L.M., Balog J., Block G.J., Santen G.W., et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat. Genet. Dec 2012, 44(12):1370-1374.
63. Stadler G., Rahimov F., King O.D., Chen J.C., Robin J.D., Wagner K.R., et al. Telomere position effect regulates DUX4 in human facioscapulohumeral muscular dystrophy. Nat. Struct. Mol. Biol. Jun 2013, 20(6):671-678.
64. Snider L., Geng L.N., Lemmers R.J., Kyba M., Ware C.B., Nelson A.M., et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet. Oct 2010, 6(10):e1001181.
65. Zeng W., de Greef J.C., Chen Y.Y., Chien R., Kong X., Gregson H.C., et al. Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet. Jul 2009, 5(7):e1000559.
66. Himeda C.L., Debarnot C., Homma S., Beermann M.L., Miller J.B., Jones P.L., et al. Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene. Mol. Cell. Biol. Jun 2014, 34(11):1942-1955.
67. de Greef J.C., Wohlgemuth M., Chan O.A., Hansson K.B., Smeets D., Frants R.R., et al. Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD. Neurology Sep 4 2007, 69(10):1018-1026.
68. de Greef J.C., Lemmers R.J., van Engelen B.G., Sacconi S., Venance S.L., Frants R.R., et al. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum. Mutat. Oct 2009, 30(10):1449-1459.
69. Munsat T.L., Piper D., Cancilla P., Mednick J. Inflammatory myopathy with facioscapulohumeral distribution. Neurology Apr 1972, 22(4):335-347.
70. Wulff J.D., Lin J.T., Kepes J.J. Inflammatory facioscapulohumeral muscular dystrophy and Coats syndrome. Ann. Neurol. Oct 1982, 12(4):398-401.
71. Tawil R., McDermott M.P., Pandya S., King W., Kissel J., Mendell J.R., et al. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY group. Neurology Jan 1997, 48(1):46-49.
72. Benson D.W., Foley-Nelson T., Chance W.T., Zhang F.S., James J.H., Fischer J.E. Decreased myofibrillar protein breakdown following treatment with clenbuterol. J. Surg. Res. Jan 1991, 50(1):1-5.
73. Maltin C.A., Hay S.M., McMillan D.N., Delday M.I. Tissue specific responses to clenbuterol; temporal changes in protein metabolism of striated muscle and visceral tissues from rats. Growth Regul. Dec 1992, 2(4):161-166.
74. van der Kooi E.L., de Greef J.C., Wohlgemuth M., Frants R.R., van Asseldonk R.J., Blom H.J., et al. No effect of folic acid and methionine supplementation on D4Z4 methylation in patients with facioscapulohumeral muscular dystrophy. Neuromuscul. Disord. Nov 2006, 16(11):766-769.
75. Patel K., Amthor H. The function of myostatin and strategies of myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle. Neuromuscul. Disord. Feb 2005, 15(2):117-126.
76. Wagner K.R., Fleckenstein J.L., Amato A.A., Barohn R.J., Bushby K., Escolar D.M., et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. May 2008, 63(5):561-571.
77. Bosnakovski D., Choi S.H., Strasser J.M., Toso E.A., Walters M.A., Kyba M. High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity. Skelet. Muscle Feb 1 2014, 4(1):4.
78. Vilquin J.T., Marolleau J.P., Sacconi S., Garcin I., Lacassagne M.N., Robert I., et al. Normal growth and regenerating ability of myoblasts from unaffected muscles of facioscapulohumeral muscular dystrophy patients. Gene Ther. Nov 2005, 12(22):1651-1662.
79. Morosetti R., Mirabella M., Gliubizzi C., Broccolini A., Sancricca C., Pescatori M., et al. Isolation and characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies. Stem Cells 2007, 25(12):3173-3182.
80. van der Kooi E.L., Lindeman E., Riphagen I. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst. Rev. Jan 25 2005, 1:CD003907.
81. van der Kooi E.L., Vogels O.J., van Asseldonk R.J., Lindeman E., Hendriks J.C., Wohlgemuth M., et al. Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology Aug 24 2004, 63(4):702-708.
82. Colson S.S., Benchortane M., Tanant V., Faghan J.P., Fournier-Mehouas M., Benaim C., et al. Neuromuscular electrical stimulation training: a safe and effective treatment for facioscapulohumeral muscular dystrophy patients. Arch. Phys. Med. Rehabil. May 2010, 91(5):697-702.